{
  "id": 12413746,
  "title": "Needham reiterates Buy on Stryker stock after CEO transition plan",
  "url": "https://urgent.news/2026/10/06/needham-reiterates-buy-on-stryker-stock-after-ceo-transition-plan",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T15:34:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/needham-reiterates-buy-on-stryker-stock-after-ceo-transition-plan-93CH-4934953"
  },
  "original_language": "en",
  "account": "Needham has maintained its \"Buy\" rating and $418.00 price target for Stryker Corporation (NYSE:SYK) after the medical device maker unveiled a plan to transition its leadership. Currently trading at $280.82, the company's shares are near their 52-week low of $267, though InvestingPro analysts believe the stock is undervalued. Stryker announced that Spencer Stiles, currently President and Chief Operating Officer, will assume the role of CEO starting January 1, 2027, replacing Kevin Lobo. Lobo, who has been CEO since 2012, will take on the role of Executive Chair of the Board. During Lobo's tenure, Stryker's revenue expanded from about $9 billion in 2012 to an estimated $26 billion in 2026, with over 60 acquisitions integrated, including the MAKO Surgical acquisition in 2013. The company boasts a market capitalization of $107.74 billion and reported $25.84 billion in revenue over the past year, with an 8.5% growth rate. Stryker has a strong financial track record, having increased its dividend for 16 consecutive years and earning a perfect Piotroski Score of 9, indicating robust financial health. Stiles has been with Stryker since 1999, serving in various leadership roles across Orthopaedics, MedSurg, and Neurotechnology, including leading the acquisition of Wright Medical Group in 2020. Needham credits Stryker for successfully implementing a succession plan, promoting Stiles to President and COO in late 2025. Recent analyst revisions have impacted Stryker's stock, with Stifel adjusting its price target to $330, citing revenue pressures and a revised organic growth estimate of 8.3% for 2026, which is on the lower end of the company's guidance. TD Cowen lowered its price target to $298, with revised third-quarter 2026 revenue and earnings estimates of $6,625 million and $3.56 per share, respectively, slightly below the consensus. Canaccord Genuity reduced its price target to $385 due to manufacturing challenges in Stryker's Peripheral Vascular unit, while BMO Capital revised its target to $317, forecasting a 10.2% third-quarter organic growth following recent conference comments. Despite these adjustments, several firms, including Canaccord and BMO, still maintain a positive outlook with Buy and Outperform ratings, respectively. These updates highlight the challenges and expectations facing Stryker in the upcoming quarters. This report was generated with AI assistance and reviewed by an editor.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Stifel reiterates Kamada stock Buy rating on biosimilar expansion",
        "url": "https://urgent.news/2026/10/06/stifel-reiterates-kamada-stock-buy-rating-on-biosimilar-expansion",
        "published": "2026-10-06T15:02:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}